Strengthening collaboration and innovation
to address joint healthcare challenges
beyond COVID
EFPIA Japan Days
6 October 2022
Mr. Hubertus von Baumbach
President of EFPIAEFPIA’s vision: work together for patients in thesechallenging times
Industry contributing to patients, healthcare systems and societies overall

Defeat COVID-19 and
Build Back Better

Europe and Japan as strong
drivers in life sciences

Renewing industry’ssocietal contract

INDUSTRY TAKESRESPONSIBILITY TO TACKLECURRENT CHALLENGESAND STRENGTHEN LONGTERM HEALTH RESILIENCE

INDUSTRY WANTS
EUROPE AND JAPAN TOBECOME GLOBALINNOVATION LEADERS
FOR THE BENEFIT OF
PATIENTS

INDUSTRY IS COMMITTEDTO ACHIEVING THE
COMMON GOAL OF
BUILDING A FUTUREPROOF HEALTHCARE AND
INNOVATION SYSTEM

www.efpia.eu2

Industry is delivering since 2020: producing and making available
COVID-19 vaccines and treatments
The COVID-19 pandemic

Industry commitments: 1) Unparalleled R&D efforts and cooperation; 2) Ramped up
production in record time
Vaccines: Global need for vaccines has been met (15 billion to date) and R&D is ongoing
Therapeutics: Already today, there is no shortage of COVID-19 treatments and accessinitiatives are in place. Only 37 treatments (2.0% of all treatments in development) havereceived regulatory approval so far
Production of therapeutics exceeds demand for allvariants, disease severity levels and patient settings

Source: Airfinity (8 September 2022)

COVID-19 treatments pipeline (n = 1,813)

www.efpia.eu

3

Weakening IP through an extension of the TRIPS waiver totherapeutics and diagnostics damages innovation
In June WTO members agreed to waive IP rights (“TRIPS Waiver”) for COVID- 9qbg b ”“But COVID-19 vaccine production already exceeded global demand and IP was not a bottleneck.
For therapeutics today: there is no shortage of COVID-19 treatments and access programs are
already successfully in place. So: there is no problem to solve for a waiver extension.
What are the effects of an extension?

It can hurt patientsIts scope will spill-over to other therapy areas
It will damage innovation in countries with strong IP

There are 16 Japanesecompanies developing
37 candidates astreatments for COVID19

It will have a negative impact on growth, jobs,investments, and exports.
It serves some waiver proponents with domestic
industrial policy agendas.

It sets a precedent that can spread to other key
sectors including digital and green technologies.

Source: Airfinity (8 September 2022)

www.efpia.eu

4

R&D is needed to meet broader patient needs
Other diseases did not go away

Growing global populations and ageing societies
Chronic diseases are expected to make up 70% of all illnesses
Rare diseases and cancer need R&D to find treatments and cures
CANCER

3.4 millionDiagnoses/year

EU: Beating Cancer Plan
Japan: Cancer control programmes

ALZHEIMER’S

14 million
patients by 2030
in EU

EU: Act on Dementia plan
Japan: New Orange Plan

https://www.efpia.eu/media/412957/efpia-2018-annual-report.pdf

DIABETES

14 million
Diagnosesby 2045

Japan: Diabetes control programs‘g ’ – Japan Times)
EU: Joint Action on Chronic Diseases
and Promoting Healthy Ageing
across the Life cyclewww.efpia.eu

5Innovation pipeline is exciting and transformative
Illness never sleeps, so neither do we

5.000 clinical trials started in 2020 alone, across many therapeutic areas, fromthose with high societal impact to rare diseases – driven by patient need.

Source; IQVIA (2020)

www.efpia.eu

6

Opportunities for collaboration in R&D andinnovation.
Collaboration between the EU and Japan

No one country, sector or stakeholder can solve the current healthcare
challenges alone: cooperation and joint research are key.

EU: Innovative Health Initiative (IHI), a Public-Private Partnership (50% paid by; %b
E ,E “H z E”
programmeHorizon Europe and the Innovative Health Initiative are open to the Japanese
research community. Japan and EU are now exploring possibility of Japanjoining Horizon Europe as an association country, the closest form ofinternational cooperation on research and innovation.

EFPIA welcomes the EU-Japan Digital Partnership, launched during the EUJapan Summit in May 2022 and will work with EU and Japanese stakeholders toleverage opportunities in research, innovation and healthcare efficiency.

https://www.efpia.eu/media/412957/efpia-2018-annual-report.pdf

www.efpia.eu

7

The global R&D landscape has been changing
R&D investments

Big changes in shares ofR&D investments occurred
between 2001 and 2020:
Japan from 14% to 9%
EU+UK+CH from 41% to 31%

US from 44% to 52%
China from 1% to 8%
The EU and Japan shouldtake (joint) actions to up
their R&D and investment
attractiveness or risk
continue to lose R&D
investment shares to global
competitors.

https://www.efpia.eu/media/412957/efpia-2018-annual-report.pdf

www.efpia.eu

8International collaboration is more than everneeded to deliver solutions for patients
Borderless Partnership• Develop new medicines in
global partnerships• Create value for the healthcare
system in Japan• Create value for patients withnew medicines and treatments

Industry capability andGlobal Leadership

Driving growth andsocietal health• Strengthen R&D environment
for the innovative pharmaceutical industry in Japan• Create economic growth andinvestments via a stable,
predictable and pro-innovation
environment• Japan and EU should create
value as global leaders with
their top-level regulatory
frameworks• Create societal value by
promoting access andsupporting a healthier society

By joining forces, the EU and Japan will be stronger together. Industry
offers its commitment to the EU and Japanese markets to createsynergies for patients, healthcare systems and both societies.

www.efpia.eu

9For further questions or inquiries, please contact:• Dr. Koen Berden, Executive Director for International Affairs at EFPIA(koen.berden.ext@efpia.eu); or• Mr. T. Morooka, Director-General of EFPIA Japan(takeo.morooka@efpia.jp)